Commentary on ‘Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)’ | Zendy

Reiersen Angela M. | Zendy; Handen Benjamin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Commentary on ‘Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)’

Author(s) -

Reiersen Angela M.,

Handen Benjamin

Publication year - 2011

Publication title -

evidence‐based child health: a cochrane review journal

Language(s) - English

Resource type - Journals

ISSN - 1557-6272

DOI - 10.1002/ebch.786

Subject(s) - cochrane collaboration , autism , systematic review , psychiatry , medicine , psychology , medline , meta analysis , cochrane library , political science , law

This is a commentary on a Cochrane review, published in this issue of EBCH, first published as: Williams K, Wheeler DM, Silove N, Hazell P. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database of Systematic Reviews 2010, Issue 8. Art. No.: CD004677. DOI: 10.1002/14 651 858.CD004677.pub2. Further information for this Cochrane review is available in this issue of EBCH in the accompanying Summary article. Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. The Cochrane Collaboration

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research